thumbnail image

#NPGS

  • HOME
  • ABOUT
  • VIDEO LIBRARY
  • …  
    • HOME
    • ABOUT
    • VIDEO LIBRARY

    #NPGS

    • HOME
    • ABOUT
    • VIDEO LIBRARY
    • …  
      • HOME
      • ABOUT
      • VIDEO LIBRARY
      • TIME ZONES

      • NPGS 2021 Agenda

        Following the success of the inaugural 2020 event and valuable feedback from attendees, the 2021 programme will look slightly different - with a focus on broader research topics that are open and accessible to all. Each session will include the opportunity to discuss and ask questions to the presenting experts in neuroblastoma. Alongside these sessions, specialised conversation rooms offer families who have specific interests the opportunity to come together, network and share their experience, covering topics such as CNS relapse and adults living with neuroblastoma.
      • Friday 5 November

        CURRENT RESEARCH - Personalised Medicine and Zero Childhood Cancer Project (including PRISM)

        6:00-6:50 London Time
         

        Dr. David Ziegler presents on the promising area of personalised medicine and focuses on Australia's PRISM trial which is being extended to include more childhood cancer patients.  This session is hosted by NPGS 2021 as part of the Neuroblastoma Australia Family Conference running in parallel. 
        Moderated by Lucy Jones.
        A Q&A will follow.

        CURRENT RESEARCH DIRECTIONS: Polyamine Inhibition Projects, CBL0137, BCT-100 and New Discoveries

        7:00-7:50 London Time
         

        Dr. Murray Norris presents on some of the exciting research being done by Children's Cancer Institute at Randwick including some recently discovered findings.  This session is hosted by NPGS 2021 as part of the Neuroblastoma Australia Family Conference running in parallel. 
        Moderated by Lucy Jones.
        A Q&A will follow.

        WELCOME

        16:00-16:15 London Time
         

        Dr. Daniel Morgenstern will welcome you to the event and share a message from Chair of the Children's Oncology Group Neuroblastoma Disease Committee in North America.

        COPING WITH DIAGNOSIS

        16:15-18:05 London Time
         

        Covering topics including neuroblastoma basics and an overview of standard treatment, this session will provide a deeper understanding of the neuroblastoma landscape for families who are facing a recent diagnosis.
        Moderated by Donna Ludwinski.
        • Neuroblastoma basics and terminology with Dr. Ramya Ramanujachar
        • Overview of treatment for high-risk neuroblastoma with Dr. Daniel Morgenstern
        • Advances in imaging for neuroblastoma with Dr. Julie Park
        • Dealing with acute side effects with neuroblastoma nurse practitioner, Jennifer Saggio
        Followed by a 45 minute Q&A.

        CONVERSATION ROOM: ATRX Mutated Disease

        16:15-17:15 London Time
         

        This conversation room is for parents of children with ATRX mutated neuroblastoma to speak directly about their knowledge and experience. This room will be facilitated by fellow neuroblastoma parent, Sarah Moore, who has advanced knowledge on the topic.

        IF TREATMENT DOESN'T GO TO PLAN

        18:20-20:10 London Time
         

        Focusing on a common concern in the neuroblastoma community, this session will look at the latest developments in care for relapse and refractory disease, including a parent perspective on the importance of hope.
        Moderated by Gavin Lindberg.
        • Overcoming refractory disease with Dr. John Maris
        • Relapse strategies including a snapshot of current trials with Dr. Pablo Berlanga
        • Maximising the potential of MIBG therapy with Dr. Kate Matthay
        • What is Hope? with Lara Cady Weberling
        Followed by a 45 minute Q&A.

        PROGRESS IN NEUROBLASTOMA CLINICAL TRIALS: where we’ve come from & where we’re going

        20:45-21:40 London Time
         

        Josiane Demetriou will host this year’s special interest talk with Dr. Toby Trahair, looking at progress in the treatment of neuroblastoma, what the future holds and what can be done to address challenges that remain.  
        Followed by a Q&A.
      • Saturday 6 November

        MAINTENANCE THERAPIES

        15:00-16:20 London Time
         

        This session will cover the latest updates on common maintenance therapies including the Bivalent Vaccine study and DFMO study.
        Moderated by Helen McCarthy-Tennant.
        • Vaccine study updates with Dr. Shakeel Modak
        • DFMO study updates with Dr. Giselle Sholler
        • Options for relapsed neuroblastoma after achieving a response or stabilisation of disease with Dr. Lucas Moreno
        Followed by a 45 minute Q&A.

        CONVERSATION ROOM - CNS Relapse

        15:00-16:00 London Time
         

        This conversation room is a space for parents to discuss CNS relapse in neuroblastoma. It will be facilitated by Antonia Palmer, neuroblastoma parent and Executive Director of the Kindred Foundation, who has advanced knowledge on the topic.

        THE ROLE OF HIGH-DOSE CHEMOTHERAPY IN NEUROBLASTOMA

        16:35-17:35 London Time
         

        High-dose chemotherapy is a common standard treatment for high-risk neuroblastoma- but there isn’t universal agreement on its continued use. In this session, Dr. Daniel Morgenstern will present a summary of the latest discussions from the recent SIOP meeting, addressing both the pros and cons of this treatment pathway. 
        Nick Bird will also speak on the parent perspectives around using high-dose chemotherapy for neuroblastoma, and there will be opportunity for open discussion at the end of the talks.

        ADVANCES IN IMMUNOTHERAPY FOR RELAPSE/REFRACTORY

        17:50-19:25 London Time
         

        Could immunotherapy be a key to treating cases of relapse or refractory disease? Experts will present the latest developments in ongoing trials and new combination therapy studies that hope to answer this question.
        Moderated by Nick Bird.
        • Updates on Naxitamab and Omburtamab with Dr. Jaume Mora
        • Chemoimmunotherapy combinations with Dr. Rajen Mody
        • Exploring the role of anti-CD47 with Dr. Robbie Majzner
        Followed by a 45 minute Q&A.

        SURVIVORSHIP

        19:40-21:00 London Time
         

        Dr. Lisa Diller provides an overview of issued faced in this Q&A session focused on the hopes and challenges of life after treatment. In addition, neuroblastoma survivors will join, led by Pat Tallungan, to share their experiences.

        CLOSING REMARKS

        21:00-21:15 London Time
         

        Symposium Host Dr. Daniel Morgenstern will close this year’s event, with a montage of the children from around the world who we are here to support and champion.

      Contact Us

      SKC UK Privacy Policy

      SKC US Privacy Policy

      NPGS Video Library

      © 2021

        Cookie Use
        We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
        Learn More